

Review of Patient Management Process and Recommendations in TG203

Moyed Miften, Ph.D.

Professor and Chief Physicist

Department of Radiation Oncology

University of Colorado School of Medicine



Acknowledgement


- TG203 members



Patient with CIED in RT clinic


Management Process

- Initial visit/consult
- Simulation
- Treatment planning
- Risk categorization and consultation
- Treatment
- Monitoring
- Follow up



Initial Visit Consult: Physician and Nurse

- Identify the CIED patient
- Place CIED alert in chart
- Place a copy of CIED identification card in chart
- CIED evaluation by cardiology/electrophysiology prior to treatment including checking for pacing dependence if needed
- Notify physics, dosimetry, and therapy



Simulation

- Studies have shown a small risk to CIED from CT irradiation.
- Most common effect observed was oversensing
- Effects were transient and were only observed during direct irradiation of the CIED generator
- Exclude the CIED from the scan when the anatomy in the CIED area is not needed for diagnosis, delineation, and dose calculations



Treatment Planning

- Avoid direction irradiation of CIED
- Beam energies ≤ 10 MV should be used
- TPS should be used in lieu of a measurement if CIED is within 3 cm (laterally) of the field edge or 5% isodose line for IMRT.
- Record the approximate distance from the field edge to the CIED and record distance in chart
- Perform in vivo dosimetry for the first fraction if CIED is > 3 cm and <10 cm from treatment fields.
- Adjust imaging fields to not irradiate CIED.



Physicist Role

- Contact manufacturer and place manufacturer guidelines in chart
- Perform in-vivo measurement if needed by placing detector on the nearest part of the CIED to the field
- Compare in-vivo measurement results to manufacturer guidelines
- Notify physician of in-vivo measurement results and document in chart
- Check plan and verify guidelines are being followed



Physician Role

- Consult physics/dosimetry to assess dose to the CIED
- Order in-vivo measurement when appropriate
- CIED should not fall directly within the radiation field
- Assess RT risk to CIED using TG203 and manufacturer guidelines
- Consult with cardiology/electrophysiology, and in conjunction, determine the risk level (low, medium, or high)
- On treatment orders will be based on risk level and electrophysiologist recommendations
- Follow TG203 or inhouse guidelines for monitoring during treatment




Recommendation to use ≤ 10 MV beams

- Reduce the risk of a Single Event Upset (SEU) in memory or logic circuits caused by neutrons (soft errors)
 - Changes in stored values in memory or transient changes in micro-processor circuitry
 - Reset of the device causing reversion to default parameters
 - Rare cases where reset may delay for hours or even weeks post-treatment
- There is some neutron production from 10 MV beams (and even at lower energies), however, the neutron flux increases dramatically above 10 MV



SEU Events and High Energy Beams

- Data from Grant et al (JAMA 2015)
 - 215 patients with ICPs and ICDs treated in various sites
 - CIED Median 0.50 Gy; range: 0–30.2 Gy
 - 15 SEU events (attributed to neutrons from > 10 MV beams), 2 unrecoverable, 3 transient noise events.
- Mouton et al (PMB 2002) reported changes in CIED output for an 18 MV beam
 - total doses was as low as 0.15 Gy,
 - changes are likely due to a SEU induced by neutrons




Risk Categories

- CIED malfunction mainly increases with
 - Cumulative dose
 - Neutrons present in the beam

	< 2 Gy	2-5 Gy	> 5 Gy or Neutrons
pacing-independent	Low risk	Medium risk	High risk
pacing dependent	Medium risk	Medium risk	High risk

- Cumulative dose < 5 Gy
- Avoid high energy photons (>10MV), proton or neutron beams



Low-Risk (< 2 Gy)

Department	Staff
<ul style="list-style-type: none">• Resuscitation protocol• Pacemaker magnet, pulse oximetry, and AED available at treatment unit.• Close monitoring of the CIED patient with an audio-visual system during treatment• ICD patients: program tachycardia off or use magnet• Communication with cardiology/electrophysiology	<ul style="list-style-type: none">• CIED check before 1st fraction and after last fraction• Radiation oncologist and QMP available with sufficient knowledge in the management of CIED patients.• Therapists should be experienced in the management of CIED patients



Medium-Risk (2-5 Gy)

Department	Staff
<p data-bbox="69 337 562 434">Low-Risk requirements AND</p> <ul data-bbox="69 456 938 907" style="list-style-type: none"><li data-bbox="69 456 658 558">• Formal consultation with electrophysiology.<li data-bbox="69 572 807 732">• Pacing dependent: consult with electrophysiology on the use of magnet and pulse oximetry.<li data-bbox="69 746 938 907">• Appropriate cardiac support available to manage complications from potential CIED malfunctions.	<p data-bbox="996 337 1489 434">Low-Risk requirements AND</p> <ul data-bbox="996 456 1843 554" style="list-style-type: none"><li data-bbox="996 456 1843 554">• CIED technologist to interrogate the device at mid-treatment.



High-Risk (> 5 Gy or Neutrons)

Department	Staff
<p data-bbox="69 336 649 383">Medium-Risk requirements</p> <p data-bbox="459 396 562 437">AND</p> <ul data-bbox="83 454 653 500" style="list-style-type: none"><li data-bbox="83 454 653 500">• ECG monitoring weekly.	<p data-bbox="1010 336 1590 383">Medium-Risk requirements</p> <p data-bbox="1387 396 1489 437">AND</p> <ul data-bbox="1010 454 1725 790" style="list-style-type: none"><li data-bbox="1010 454 1725 500">• Trained staff examines ECG.<li data-bbox="1010 511 1725 615">• CIED technologist should be available, if needed.<li data-bbox="1010 626 1725 790">• Technologist to interrogate the device weekly once the device receives > 5 Gy.



Other Recommendations

- Verify the CIED compatibility prior to MR simulating the patient and ensure device is MR conditional
- Contact the device manufacturer to ensure the device compatibility with the magnetic field strength used for simulation
- Low dose-rates of < 0.01 Gy/min to the device should be maintained (soft recommendation)




Use of Magnets During RT

- The use of a magnet over an ICD
 - temporarily inhibit defibrillation therapy while it is applied.
 - cardiology may require additional monitoring of the patient during treatment in case defibrillation is required.
- The use of a magnet over an ICP
 - turns the sensing function off and sets the pacemaker to a preprogrammed asynchronous mode (usually 70-90 bpm)
 - ignore any sensed activity and is therefore asynchronous to any intrinsic patient heart rhythm
- Cardiology/electrophysiology should be consulted



Magnet on ICP





Patient with Carcinoma of the Uterus

- 68 yo patient implanted with ICP, pacing dependent
- Whole pelvis treated to 40 Gy in 20 fractions Gy using 6MV VMAT followed by 8.5 Gy x 2 HDR to uterus
- ICP > 10 cm from treatment fields
- Patient was completely dependent on her pacemaker as her underlying rhythm during device interrogation showed complete heart block with no ventricular escape.
- Magnet on ICP during treatment
- Heart rate monitoring, to ensure proper magnet placement, is utilized during treatments





Patient with intimal sarcoma of the left atrium

- 68 yo patient implanted with ICP, pacing dependent
- Hypofractionated chemoradiation to 34.5 Gy in 15 fractions using 6MV VMAT
- ICP dose 42 cGy
- Managed following consultation with the device clinic as high risk with daily device checks
- Magnet on ICP with every treatment



Patient with left hilar mass encasing the left pulmonary artery

- 68 yo patient implanted with ICD
- Treated to 30 Gy in 10 fractions using 6MV 3DCRT
- ICD dose 428 cGy
- Patient is medium risk: checks at pre-, mid-, and post-treatment
- Magnet on ICD with every treatment



Summary

- Management of RT patients with a CIED is essential.
- Safe medical practice requires that the risk to patients CIED be reduced as much as possible.
- The risk of CIED malfunction should be weighed against other medical risks the patient may be subjected to.
- The quality of radiotherapy and the risk of tumor recurrence should not be comprised for the sake of reducing the risk to a CIED which is comparatively low.



Thank You

